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Background: Most human tumors escape 
immune system because of the 
immunosuppressive tumor microenvironment. 
Results: N-acetyllactosamine units, the ligands 
for galectin-3, and branching on N-linked 
glycans are increased in the recently activated 
cytolytic T lymphocytes. 
Conclusion: The increased galectin-3-lattices 
decrease the motility of key surface 
glycoproteins. 
Significance: Loss of effector functions on 
cytolytic T lymphocytes may be linked to 
reduced motility of surface glycoproteins. 
SUMMARY 
Most human tumors are not eliminated by the 
immune system and therapeutic vaccination 
shows poor results, a fact that can be 
explained, at least partially, by an 
immunosuppressive tumor microenvironment 
which is abundant in galectin-3. On cytolytic 
T lymphocyte (CTL) clones, maintained in 
culture by regular stimulation, recently 
activated CTLs present low effector functions. 
However, these functions are restored after a 
short treatment with LacNAc. The latter, 
which is in agreement with the glycoprotein-
galectin lattice concept involving reduced 
motility, poses the question why galectin-3 
ligands improve effector functions. We 
employed ultra-sensitive MALDI-TOF-MS on 
resting and recently activated CTL clones, 
combined with various glycosidase digestions 
and GC-MS linkage analyses. Our results 
showed that compared with the resting CTLs, 
the N-glycans of the recently activated CTLs 
consisted of: (i) larger LacNAc oligomers of 
which a significant portion was longer than 
four-units; (ii) more multi-antennary 
structures. Interestingly, our results showed 
that the poly-LacNAc appeared to be equally 
distributed on all available N-glycan branches 
and not selectively enriched on a specific 
branch. The above structural alterations in 
the recently activated CTLs are expected to 
increase the galectin-3-LacNAc lattices and 
multivalent interactions and therefore reduce 
the motility of surface glycoproteins, such as 
the TCR. These findings suggest that the loss 
of effector functions on CTLs may be linked 
to reduced motility of surface glycoproteins. 
In addition, our results showed that recently 
activated CTLs had a reduced abundance of 
NeuAcα2,6-linked N-glycans and an increased 
abundance of disialylated core 1 and 
monosialylated core 2 O-glycan structures. 
Human tumors are usually not 
spontaneously eliminated by the immune system 
and therapeutic vaccination of cancer patients 
with defined antigens is followed by tumor 
regressions only in a small minority of patients 
(1, 2). The poor vaccination effectiveness could 
be explained by an immunosuppressive tumor 
microenvironment. Because T cells that do 
infiltrate tumor metastases have an impaired 
ability to lyse target cells or to secrete cytokines 
when they are stimulated ex vivo, i.e. tested on 
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untreated and uncultured samples (3-7), many 
researchers are trying to decipher the underlying 
immunosuppressive mechanisms.  
We suggested that extracellular galectin-3, 
abundant in solid tumor and carcinoma ascites, 
impairs human tumor-infiltrating T lymphocyte 
(TIL)2 function (8). The motility of surface 
molecules, such as the T-cell receptor (TCR), 
which are necessary for T cell activation and 
function, can be reduced because they are 
trapped in a lattice of glycoproteins clustered by 
extracellular galectin-3 (9). Several of our 
results support this hypothesis. First, human 
tumor-infiltrating CD8+ T lymphocytes (TIL) 
from diverse histological origins, in contrast 
with CD8+ blood cells, have an impaired ability 
to secrete IFN-γ upon ex vivo stimulation (6). 
We documented by FRET, the physical 
dissociation of TCR and CD8 on these TIL. 
Second, TIL harbour surface galectin-3 which 
can be detached by treatment of CD8+ TIL with 
an anti-galectin-3 antibody. A 2-h treatment of 
TIL with this antibody, followed by overnight 
stimulation with beads coated with anti-CD3 
antibodies, that mimic an antigenic stimulation, 
boosted their secretion of IFN-γ (6). Third, two 
galectin ligands, N-acetyllactosamine 
(Galβ1,4GlcNAc; LacNAc) and GCS-100, a 
modified citrus pectin, detached galectin-3 from 
TIL, promoted co-localization of TCR and CD8 
co-receptor and increased their cytotoxicity and 
their ability to secrete IFN-γ upon stimulation 
(6). It has to be noted that both galectin ligands 
are also able to detach galectin-1 from cells.  
We also analysed the effect of galectin 
ligand LacNAc on cytolytic T lymphocyte 
(CTL) clones maintained in culture by regular 
antigenic stimulation, i.e. every two weeks. 
Compared with resting CTL collected 14 days 
after the last stimulation, recently activated CTL 
that were collected 4 days after stimulation 
secreted low levels of IFN-γ upon a further 
antigenic stimulation (8). We documented by 
FRET and by confocal microscopy the physical 
dissociation of TCR and CD8 at the surface of 
recently activated lymphocytes whereas TCR 
and CD8 were co-localized on most of the 
resting cells. In agreement with the hypothesis of 
a glycoprotein-galectin lattice on recently 
activated CTL, a short treatment of these CTL 
with LacNAc increased the proximity between 
TCR with the CD8 and restored their ability to 
secrete high levels of IFN-γ. 
Experiments in mice models have revealed 
the influence of N-glycans on T cell activation. 
Firstly, T cells from mice lacking N-
acetylglucosaminyltransferase V (Mgat5), an 
enzyme essential for the generation of complex 
tetra-antennary N-glycans, have a lower 
activation threshold than T cells from wild type-
mice. The tetra-antennary N-glycans can carry 
poly-LacNAc chains, the natural ligands of 
galectin-3. Mgat5-deficient mice showed 
evidence of immune dysfunction by increased 
sign of proliferative glomerulonephritis and 
were more susceptible to develop autoimmune 
encephalomyelitis (9). Secondly, T cells from 
mice lacking β1,3-N-
acetylglucosaminyltransferase 2 have reduced 
poly-LacNAc on their N-glycans and were much 
more sensitive to activation upon stimulation 
with anti-CD3 coated beads (10). Finally, Kuball 
et al. introduced mutations in a TCR coding 
sequence that destroy N-glycosylation sites (11). 
These modified sequences were grafted in 
polyclonal T cells, which acquire a better avidity 
for the antigen recognized by the grafted TCR 
than T cells carrying the wild-type TCR. The 
authors proposed that glycosylation affects the 
flexibility, movement, and interactions of 
surface molecules, but it cannot be excluded that 
these mutations also affect the number of 
galectin ligands and the possibility to form TCR-
galectin lattices.  
Why do galectin ligands improve effector 
functions of human TIL and CTL clones? Our 
working hypothesis is that, as a consequence of 
antigen-stimulated activation of T cells, the 
expression of enzymes of the N-glycosylation 
pathway is modified, and this changes the 
structures of N-glycans exposed at the cell 
surface. In agreement with that hypothesis, when 
resting CTL were stimulated in the presence of 
swainsonine, a inhibitor of α-mannosidase II 
which is involved in the N-glycosylation 
pathway, recently activated CTL collected at day 
4 after stimulation, compared to untreated cells, 
showed a higher TCR-CD8 FRET efficiency and 
a higher ability to release IFN-γ upon antigenic 
stimulation (8). We surmise that the recently 
activated TIL, compared to resting T cells, 
harbour a set of glycans that are either more 
numerous or better ligands for galectin-3, and 
possibly for other galectins, such as galectin-1. 
In vivo, tumor cells, macrophages, and possibly 
activated T cells can secrete galectin-3. In in 
vitro cultures of CTL clones, galectin-3 can be 
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secreted by the tumor cells used as stimulators, 
the immortalized B cells used as feeder cells, 
and possibly by the activated T cells themselves. 
Indeed, expression of galectin-3 is increased 
after murine T cell activation by the mitogen 
ConA. Also, galectin-3 secretion is enhanced in 
response to calcium ionophore when T cells are 
previously activated (12).  
N-glycans harboured by murine splenocyte 
T cells have been previously compared with 
those found at the surface of splenocyte T cells, 
which were activated by anti-CD3 antibody and 
collected three days later. Activation resulted in 
a decreased expression of the sialyltransferase 
ST6Gal1 and increased expression of the 
galactosyltranferase α1,3GalT (13). 
Accordingly, activation resulted in reduction of 
sialylated biantennary N-glycans carrying the 
terminal NeuGcα2,6Gal sequence, and a 
corresponding increase in glycans carrying the 
Galα1,3Gal sequence. Murine T cells, however, 
are not good models for potential galectin-
mediated processes in the human immune 
system because they are poor in tri- and tetra-
antennary poly-LacNAc glycans (14).   
Here, we characterised global changes in 
N- and O-glycans of two human CTL clones that 
were analysed either in a resting state or four 
days after antigenic stimulation. Applying ultra-
sensitive matrix-assisted laser desorption-
ionisation time-of-flight mass spectrometry 
(MALDI-TOF-MS), combined with various 
glycosidase digestions and gas chromatography 
(GC) -MS linkage analyses, we present direct 
evidence that galectin-3-ligands in recently 
activated human CTLs, compared with the 
resting state CTLs, are increased. N-glycans of 
recently activated CTLs exhibited poly-LacNAc 
chains of which a portion was found longer than 
four LacNAc units. Moreover, recently activated 
CTL clones present more branched (multi-
antennary) N-glycans. Differences in the non-
reducing N-glycan terminal epitopes and O-
glycan structures are also discussed. 
EXPERIMENTAL PROCEDURES 
CTL clones and stimulation conditions— 
Anti-MAGE-3.A1 CTL clones LB2586-7/1F3.2 
(clone F3.2) and LAU147-810/A10 (clone A10) 
were described previously (8). Every two weeks, 
stimulation was performed as described. 
LacNAc was purchased from Carbosynth. 
Antigen recognition assays for CTL 
clones— CTL clones (10,000) were stimulated 
for 20 h in round-bottomed microwells, in 100 
µl of Iscove’s modified Dulbecco medium 
(IMDM), 10% human serum (HS), 0.24 mM L-
asparagine, 0.55 mM L-arginine, 1.5 mM L-
glutamine (AAG) with 10,000 HLA-A1 
irradiated allogeneic Epstein Barr virus 
immortalized B (EBV-B) cells previously 
incubated with MAGE-3 peptide EVDPIGHLY. 
Amounts of IFN-γ secreted after overnight co-
culture were measured by ELISA using 
Biosource Cytoset reagents (Invitrogen). When 
indicated, CTL clones (10,000) were previously 
incubated for 2 h in round-bottomed microwells, 
in 50 µl of IMDM, 10% HS, AAG with 2 mM 
LacNAc before adding the stimulator cells. 
Cell pellets— Cells were collected and 
washed. Dead cells were removed by a depletion 
selection strategy, using the Dead Cell Removal 
Kit (AutoMACS system, Miltenyi Biotec). Cells 
were then washed and remaining EBV-B cells 
were removed by a positive selection strategy 
using magnetic beads coated with anti-CD19 
(AutoMACS system, Miltenyi Biotec). Cells 
were finally washed in PBS, dry pelleted and 
stored at -80 °C. 
Processing of CTL clones to obtain N- and 
O-glycans— All human CTL clones (clones A10 
and F3.2) were treated as described previously 
(15). Briefly, each CTL clone (~20 million) was 
subjected to sonication in the presence of 
detergent (CHAPS), reduction in 4 M guanidine-
HCl (Pierce, Cramlington, Northumberland, 
UK), carboxymethylation and trypsin digestion. 
The digested glycoproteins were then purified by 
C18-Sep-Pak (Waters Corp, Hertfordshire, UK). 
N-glycans were released by peptide N-
glycosidase F (E.C. 3.5.1.52; Roche Applied 
Science, Burgess Hill, UK) digestion while O-
glycans were released by reductive elimination. 
Released N- and O-glycans were permethylated 
using the sodium hydroxide procedure and 
purified by C18-Sep-Pak. The results shown are 
representative of three independent experiments. 
Sialidase digestions— Cleavage of the all 
sialic acids (NeuAc) or of α2,3 specific from the 
CTL clones A10 and F3.2 was performed with a 
sialidase-A (Arthrobacter ureafaciens; E.C. 
3.2.1.18; Prozyme, GK80040) and sialidase-S 
(Spectrococcus pneumoniae; E.C. 3.2.1.18; 
Prozyme, GK80020) digestions respectively. 
Released N-glycans were incubated in 200 µl of 
50 mM sodium acetate (37 °C, pH 5.5). 170 mU 
of the enzyme were added to the sample for 24 
h. 
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Remove of fucose residues— Removal of 
all fucose residues attached to antennae of N-
glycans was performed with hydrofluoric acid 
(HF) treatment. 50 µl of HF (48% v/v) was 
added to the sample for 48 h at 4 °C. The 
reaction was terminated by drying the sample 
under a gentle stream of nitrogen. 
Galactosidase digestion— Cleavage of 
galactose residues was performed with a β(1-
3,4)-galactosidase from bovine testis (E.C. 
3.2.1.23; Prozyme, GKX-5013). Released N-
glycans were incubated in 200 µl of 50 mM 
ammonium acetate (pH 4.6, 37 °C) for 24 h. 10 
mU of the enzyme was added with a fresh 
aliquot being added after 12 h. 
Hexosaminidase digestion— Cleavage of 
β-N-acetylglucosamine residues was performed 
with a β-N-acetylhexosaminidase (Streptococcus 
pneumoniae; E.C. 3.2.1.52; Prozyme, 
GK80050). Released N-glycans were incubated 
in 200 µl of 50 mM sodium formate (pH 5.0, 37 
°C) for 24 h. 80 mU of the enzyme was added 
with a fresh aliquot being added after 12 h. 
Endo-β-galactosidase digestion— Endo-β-
galactoside (Escherichia freundii; E.C. 
3.2.1.103; Seikagaku Corp, AMS Biotechnology 
Ltd, 100455) digestion was carried out in 200 µl 
of sodium acetate (pH 5.8, 37 °C). 20 mU of the 
enzyme were added to the sample for 48 h with a 
fresh aliquot being added after 24 h. 
E. freundii endo-β-galactosidase hydrolyzes 
the internal β-galactosidic linkages of both the 
type 1 and type 2 linear polylactosamine chains 
having as a minimum structural requirement the 
structure GlcNAcβ1-3Galβ1-3GlcNAc (or β1-
4GlcNAc for type 2) (16, 17). The action of E. 
freundii endo-β-galactosidase is inhibited by 
fucosylation of residues in close proximity to the 
internal β-galactosidic linkage (16, 17). For 
example, for the mono-fucosylated structure 
Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAc, 
the cleavage at the β-galactose residue is 
inhibited by the fucose on the GlcNAc residue. 
Mass spectrometry— MS data were 
acquired using either a Voyager-DE STR 
MALDI-TOF or a 4800 MALDI-TOF/TOF 
(Applied Biosystems, Darmstadt, Germany) 
mass spectrometer. MS/MS data were acquired 
using a 4800 MALDI-TOF/TOF mass 
spectrometer. Permethylated samples were 
dissolved in 10 µl of methanol and 1 µl of 
dissolved sample was premixed with 1 µl of 
matrix (20 mg/ml 2,5-dihydroxybenzoic acid 
(DHB) in 70% (v/v) aqueous methanol), spotted 
onto a target plate and dried under vacuum. For 
the MS/MS studies the collision energy was set 
to 1 kV, and argon was used as collision gas. 
The 4700 Calibration standard kit, calmix 
(Applied Biosystems), was used as the external 
calibrant for the MS mode and [Glu1] 
fibrinopeptide B human (Sigma-Aldrich) was 
used as an external calibrant for the MS/MS 
mode. 
Analyses of MALDI data— The MS and 
MS/MS data were processed using Data 
Explorer 4.9 Software (Applied Biosystems). 
The processed spectra were subjected to manual 
assignment and annotation with the aid of a 
glycobioinformatics tool, GlycoWorkBench 
(18). The proposed assignments for the selected 
peaks were based on 12C isotopic composition 
together with knowledge of the biosynthetic 
pathways. The proposed structures were then 
confirmed by data obtained from MS/MS and 
linkage analysis experiments. 
Gas-chromatography mass spectrometry 
(GC-MS) linkage analysis— Partially 
methylated alditol acetates (PMAA) were 
prepared as previously described (15). Linkage 
analysis of PMAA was performed on a Perkin 
Elmer Clarus 500 instrument fitted with a RTX-
5 fused silica capillary column (30 m × 0.32 mm 
i.d.; Restek Corp.). The sample was dissolved in 
~20-50 µl of hexanes and injected manually (2-3 
µl). Injector temperature was set at 250 °C. 
PMAA were eluted with the following linear 
gradient oven: initially the oven temperature was 
set at 65 °C for 1 min, heated to 290 °C at a rate 
of 8 °C per min, held at 290 °C for 5 min and 
finally heated to 300 °C at a rate of 10 °C per 
min. 
RESULTS 
CTL clones A10 and F3.2 were both 
directed against MAGE-3 peptide EVDPIGHLY 
presented by HLA-A1. They were expanded in 
vitro by stimulation every 14 days, using 
peptide-pulsed HLA-A1 cells. To assess the 
effector capability of the CTL at various points 
of the stimulation cycle, cells were collected at 
either 4 days (activated) or 14 days (resting) 
after antigenic stimulation and co-culturing with 
peptide-pulsed HLA-A1 cells. Amounts of IFN-γ 
secreted by the CTL were estimated by ELISA 
in the supernatant of overnight co-cultures. 
Compared to CTL collected on day 0, CTL 
collected on day 4 secreted lower levels of IFN-γ 
upon re-stimulation (Fig. 1 and supplemental 
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Fig. S1). But, when recently activated CTLs, 
collected on day 4, were treated for 2 h with 
galectin ligand LacNAc, their ability to secrete 
high levels of IFN-γ upon re-stimulation was 
restored. On the contrary, LacNAc treatment did 
not affect IFN-γ secretion on resting CTL clones 
(supplemental Fig. S2). Extracellular galectin-1 
and galectin-3 were both detected at the surface 
of recently activated CTL. The latter CTL 
contains more galectin-1 than the resting CTL. 
No detectable galectin-3 was found on the 
resting CTL. A treatment of 2 h with LacNAc, 
on the recently activated CTL, partially detached 
both galectins (supplemental Fig. S3). To 
analyse the N- and O-glycans at the cell surface 
of resting and activated CTL, cells were 
collected at the indicated time, dead cells and 
stimulator cells were removed using a depletion 
strategy, and CTL were subsequently pelleted 
and frozen at -80 °C.  
Glycomic analysis of CTLs revealed 
differences on N- and O-glycans— The N-
glycomic profile of resting CTL clone A10 
consisted of high mannose and complex 
structures (Fig. 2A). Compositional and 
MALDI-TOF-TOF MS/MS analyses suggested 
that the latter were mainly core fucosylated and 
non-bisected, and corresponded to bi-, tri- and 
tetra-antennary N-glycan structures occasionally 
extended with LacNAc repeats. The non-
reducing ends of these glycans either remained 
unmodified (m/z 2244, 2489, 2938, 4490) or 
were further modified, mainly with terminal 
NeuAc residues (m/z 2605, 3416, 4402, 5300). 
The sLex terminal epitope was also detected in 
bi-antennary (m/z 3140, 3314) and tri-antennary 
(m/z 3951 and 4125) N-glycan structures. 
However, it was of low abundance compared 
with other terminal structures.  
The N-glycomic profile of recently 
activated CTL clone A10 exhibited similar N-
glycans to the resting state CTLs, but with the 
following differences being observed (Fig. 2B): 
(i) N-glycans with extended poly-LacNAc 
structures were of higher abundance, compared 
with the resting state, resulting in higher 
molecular weight N-glycan structures reaching 
up to 7000 mass units; (ii) sLex terminated 
glycans were of higher abundance. For example 
comparing the ratios of m/z 3140 with m/z 2966 
on both the resting and recently activated states 
(Fig. 2A and B), it was concluded that the sLex 
structures in the recently activated state were of 
higher abundance. In addition, the sLex 
containing N-glycans were overlapped with 
other most abundant structures. For example, the 
tri-antennary sLex structure detected at m/z 3951 
(Fig. 2B) was observed as a minor peak in the 
m/z 3953-ion cluster that corresponded to a 
mono-sialylated core fucosylated N-glycan.  
The O-glycomic profile of the resting CTL 
clone A10 exhibited mainly the monosialylated 
core 1 sequence (m/z 895) together with a tiny 
amount of a non-sialylated core 2 (m/z 983) 
structure (Fig. 3A). Recently activated A10 
CTLs (Fig. 3B) contained, in addition to the core 
1 O-glycan at m/z 895, disialylated core 1 O-
glycans (m/z 1256) and a higher abundance of 
core 2 O-glycans, either unmodified (m/z 983) or 
terminated with one NeuAc residue (m/z 1344) 
or with a Lex terminal epitope (m/z 1157). 
The glycomic profiles of resting and 
recently activated CTL clone F3.2 were similar 
to the CTL clone A10 structures with complex 
N-glycans being extended with LacNAc repeats 
and elaborated with the same terminal epitopes, 
while O-glycans consisted of core 1 and core 2 
structures terminated with NeuAc, Lex and 
minor abundances of sLex terminal epitopes 
(supplemental Figs. S4 and S5).  
Endo-β-galactosidase digestion revealed 
differences in the relative abundance of various 
terminal epitopes and polylactosamine-type N-
glycans— The N-glycome of CTL clones A10 
and F3.2 suggested differences in the relative 
abundance of the terminal epitopes and LacNAc 
repeats. Therefore, we performed an endo-β-
galactosidase digestion on the N-glycans of both 
CTLs (supplemental Fig. S6) with a twofold 
aim: (i) to verify whether any of the N-glycans 
of the aforementioned CTLs contained linear 
polylactosamine chains and (ii) to characterize 
and reveal any potential differences in the 
relative abundances on the non-reducing 
terminal epitopes between resting and recently 
activated CTLs. The existence of the above 
should be revealed by the new molecular ions in 
the low mass region corresponding to antennae 
fragments released by the enzyme. The low mass 
permethylated products of the CTL clone A10 in 
both states (resting and recently activated) are 
depicted in Fig. 4. Disaccharides released from 
within the polylactosamine chains gave the 
signal at m/z 518 corresponding to the GlcNAc-
Gal sequence (Fig. 4A and B). The molecular 
ions at m/z 722, 896, 1083 and 1257 were 
consistent with the terminal sequences Gal-
GlcNAc-Gal, Gal-(Fuc)GlcNAc-Gal, NeuAc-
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Gal-GlcNAc-Gal and NeuAc-Gal-(Fuc)GlcNAc-
Gal respectively which were predicted digestion 
products of uncapped, fucosylated, sialylated 
and sLex polylactosamine chains respectively. 
Evidence for the m/z 896 and 1257 components 
being terminated by Lex and sLex epitopes was 
provided by MALDI-TOF-TOF MS/MS that 
yielded major fragments at m/z 690 and 1051 
respectively (data not shown). Molecular ions at 
m/z 967, 1141, 1171 and 1345 were assigned to 
pauci-mannose N-glycan structures 
Man2GlcNAc2, Man2GlcNAc-(Fuc)GlcNAc, 
Man3GlcNAc2 and Man3GlcNAc-(Fuc)GlcNAc 
which did not correspond to fragments released 
by the endo-β-galactosidase. Moreover, endo-β-
galactosidase digestion revealed the presence of 
disialylated and Vim-2 terminal epitopes in very 
low abundance (supplemental Fig. S7). 
Analysis of the relative abundances of the 
above terminal epitopes revealed that compared 
to the resting state, the recently activated CTL 
clone A10 had higher levels of unmodified, Lex 
and sLex terminal epitopes and lower levels of 
sialylated terminal epitopes. Summing-up the 
relative abundances of all the terminal epitopes 
at m/z 722, 896, 1083 and 1257, we found that 
compared with the resting state, recently 
activated CTL clone A10 was characterized by a 
decrease in the abundance of sialylated LacNAc 
repeats at m/z 1083 (~24%) and an increase in 
the abundance of unmodified LacNAcs at m/z 
722 (~10%). Endo-β-galactosidase digestion on 
CTL clone F3.2 revealed similar abundances to 
the CTL clone A10 fragments in both states 
(supplemental Fig. S8). Uncapped, Lex, 
sialylated and sLex polylactosamine chains 
characterized the resting and recently activated 
CTL clone F3.2. Again, compared with the 
resting state, recently activated CTL clone F3.2 
was characterized by a decrease in the 
abundance of sialylated LacNAc repeats (~36%) 
and an increase in the abundance of unmodified 
LacNAcs (~196%). The reduction in glycan 
complexity on both CTL clones A10 and F3.2 
afforded by the endo-β-galactosidase digestion, 
revealed additional signals that corresponded to 
N-glycans terminated with multiples of sLex 
epitopes (supplemental Fig. S6). These signals 
existed in the original glycomic profiles but 
were in minor abundance and the isotopic cluster 
of more abundant ions partly masked them. For 
example, the ions at m/z 4761 and 4935 
corresponded to tetra-antennary N-glycans with 
a single and a double sLex epitope (supplemental 
Fig. S6A and B). 
Taken together, the endo-β-galactosidase 
digestion data on N-glycans of both CTL clones 
A10 and F3.2 confirmed the presence of 
polylactosamine chains that remained 
unmodified or were terminated with Lex, sialyl 
and sLex epitopes. The data also suggested that, 
compared with the resting state, in the recently 
activated state there was an increase in the 
relative abundance of poly-LacNAc and a 
decrease in the relative abundance of sialylated 
terminal epitopes. 
Linkage analysis revealed differences in 
polylactosamine-type abundances— The N-
glycans of both the resting and recently activated 
CTLs contain linear LacNAc units whose 
abundances appeared to be modified in the 
resting-activation CTLs cycle. Therefore, in 
order to express the percent difference of the 
polylactosamine-type chains between the resting 
and recently activated CTLs, we performed GC-
MS linkage analysis. Comparing the relative 
abundances of the 3-linked galactose and 4-
linked GlcNAc residues (that together make-up 
the LacNAc unit in poly-LacNAc) between 
resting and recently activated CTLs, we are able 
to relatively quantify the different abundance of 
the LacNAc units between the aforementioned 
CTLs. Linkage analysis was performed on 
desialylated N-glycans after digestion with 
broad specificity sialidase-A. This is because 
α2,3-linked NeuAc residues potentially could be 
linked to galactose residues and supplementing 
the 3-linked galactose from the polylactosamine-
type chains. Results from linkage analysis from 
both CTLs clones are depicted in Table 1. 
Recently activated CTL clone A10 presented a 
121% and 344% increase of the 3-linked 
galactose and 4-linked GlcNAc abundance 
respectively compared with resting CTLs, while 
for the CTL clone F3.2 the increase was 48% 
and 69% respectively. These data show that in 
both CTLs the N-glycans in the recently 
activated state contained more LacNAc chains 
than in the resting state. Additional linkage data 
confirmed structural differences between the 
resting and recently activated CTLs. For 
example the increase of 3,4-GlcNAc residues on 
the recently activated CTLs was in accordance 
with the increase of sLex epitopes. This increase 
was 363% and 29% for the CTL clones A10 and 
F3.2 respectively (Table 1). 
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Endo-β-galactosidase digestion revealed 
differences in multi-branched N-glycans— We 
next investigated whether there was a difference 
in the abundance of complex bi-, tri- and tetra-
antennary N-glycans between the resting and 
recently activated CTLs that carry LacNAc 
repeats. Endo-β-galactosidase digestion on 
resting CTL clone A10 showed that the most 
abundant N-glycans carrying LacNAc 
extensions corresponded to bi-antennary (m/z 
1836) and to a less extent to tri- (m/z 2081 and 
2285) and tetra-antennary (m/z 2326) N-glycan 
structures (Fig. 5A). On the contrary, recently 
activated CTL clone A10 showed a decrease in 
the relative abundance of bi-antennary structures 
and an increase in the abundance of tri- and 
tetra-antennary N-glycans (Fig. 5B). Summing-
up the relative abundances of the ions at m/z 
1836, 2081, 2285, 2326 and 2530, we found that 
compared with the resting state, the tri- and 
tetra-antennary N-glycans (m/z 2081, 2285, 2326 
and 2530) on the recently activated clone A10 
were increased by ~89%. The same decrease of 
the bi-antennary and increase of tri- and tetra-
antennary N-glycans was observed when resting 
and recently activated CTLs clone F3.2 were 
compared (supplemental Fig. S9). By similar 
calculations we found that the tri- and tetra-
antennary N-glycans on the recently activated 
clone F3.2 were increased by ~90%. Taken 
together, the data suggest that recently activated 
CTLs contain more branched N-glycans that 
carry LacNAc chains than the resting CTLs. 
More polylactosamine chains are found on 
recently activated CTLs— All previous 
experiments showed that the N-glycans exist as 
multi-branched structures extended with 
LacNAc repeats and terminated with various 
epitopes and that all these are modified in the 
resting-activation CTLs cycle. However, none of 
above experiments gave a cumulative indication 
on the length of these LacNAcs repeats. This 
was an important factor to consider because the 
binding affinity of galectin-3 is expected to be 
affected by the length of these LacNAc repeats 
as well as by the relative abundance of these 
terminal epitopes. Therefore, we determined the 
minimum length of the LacNAc chains on the 
resting and recently activated CTL clone F3.2 
and additionally where these poly-LacNAcs 
were mainly formed, i.e. on bi-, tri-, or tetra-
antennary N-glycans (Fig. 6).  
We removed all fucose and sialic acid 
residues substituting the antennae by 
hydrofluoric acid treatment and by a non-
specific sialidase enzymatic digestion, 
respectively, of the N-glycans of the CTL clone 
F3.2 leaving only the core-fucose and the 
LacNAc extensions (Fig. 6A, upper structure). 
Then, performing two cycles of enzymatic 
digestions with subsequent incubations of β-
galactosidase and β-N-acetylhexosaminidase, we 
reduced the N-glycan LacNAc chains of the 
CTL clone F3.2 by 2 LacNAc repeats. Finally, 
we incubated the resultant N-glycans with endo-
β-galactosidase (Fig. 6A, upper structure). The 
new signals appearing in the spectra, or the ones 
that were greatly enhanced, corresponded to N-
glycans deriving from the above process and 
their structures depended on the number of 
LacNAc repeats originally present in each 
branch (Fig. 6A, lower structure). 
According to this procedure, most of the N-
glycan structures detected on the resting and 
recently activated CTL clone F3.2 (supplemental 
Fig. S4A and B) should be fully digested to the 
basic N-glycan core structure 
Man3GlcNAc(±Fuc)GlcNAc (see Fig. 6A). 
Indeed, ions detected at m/z 1171 and 1345 
corresponded to all complex bi-, tri- and tetra-
antennary N-glycans that were extended with up 
to 2 LacNAc units that were terminated with 
Lex, sialic acid and sLex epitopes (Fig. 6B). Ions 
at m/z 1416 and 1590 corresponded to complex 
structures where one branch was extended with 
4 LacNAc repeats or more. Ions detected at m/z 
1661 and 1836 corresponded to N-glycans that 
had two branches that originally contained 4 
LacNAc repeats or more. The ions detected at 
m/z 1866, 2111 and 2285 had originally one 
branch extended with 3 LacNAc repeats and one 
or two branches (depending if they were 
bisected or not) with 4 LacNAc repeats or more 
(Fig. 6A and B). The ion detected at m/z 2530 
corresponded to a N-glycan with 2 or 3 branches 
extended with 4-LacNAc-units or more 
(depending if it was bisected or not), while the 
ion at m/z 2775 corresponded to a bisected tetra-
antennary N-glycan that had one branch 
extended with 3 LacNAc repeats while the rest 
were at least 4 LacNAc units long. Finally, the 
ions at m/z 1906, 2081, 2326 and 2571 
corresponded to bi-, tri- and tetra-antennary N-
glycans that had all of their branches extended 
with 4 LacNAc repeats or more. The above data 
suggest that a part of the resting and recently 
activated CTL clone F3.2 N-glycans had all their 
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branches extended with at least 4 LacNAc 
repeats. 
In order to express the percent difference of 
the poly-LacNAc chains between the resting and 
the recently activated CTLs, we calculated the 
relative abundance of all the N-glycans with 
more than one terminal GlcNAc and compared it 
with the summed relative abundance of the ions 
at m/z 1141 and 1345 that corresponded to N-
glycans with two LacNAc units or less. The 
results showed that compared with the resting, 
recently activated CTLs contained ~30% more 
N-glycans with one or more terminal GlcNAc 
N-glycans. Therefore, the data suggest that 
recently activated CTLs contained N-glycans 
with more branches of at least four LacNAc 
units. 
We then performed GC-MS linkage 
analysis of the above resulting N-glycans where 
any possible variations in the levels of 2,4-linked 
mannose and 2,6-linked mannose would directly 
positively correlate with the abundance of tri- 
or/and tetra-antennary N-glycans, but 
specifically for those that were elongated with 
more than 4-LacNAc units. Our data showed 
that 2,4-linked mannose and 2,6-linked mannose 
increased by ~80% and 60% on the recently 
activated clone F3.2 CTLs (supplemental Table 
S1) suggesting that more branches of at least 4-
LacNAc units were found on the recently 
activated CTLs than the resting CTLs. In 
addition, combining the data from the MALDI-
TOF-MS that indicated that the most abundant 
structure corresponded to triply terminated 
GlcNAc N-glycan (m/z 2081) and the data from 
the GC-MS linkage analysis that the 2,4-linked 
mannose residue was more abundant than the 
2,6-linked mannose residue, we concluded that 
the most abundant poly-LacNAc N-glycan 
corresponded to the tri-antennary N-glycan 
structures of GlcNAcβ1-2(GlcNAcβ1-4)Manβ1-
3. 
Recently activated CTLs have lower 
abundance of α2,6-linked NeuAc— Endo-β-
galactosidase digestion suggested that, compared 
with the resting state, there was a decrease in the 
sialylation of the N-glycans in the recently 
activated state of both CTLs. However, the 
previous experiments did not reveal any 
information concerning the linkage of the 
NeuAc residues. Therefore, we applied α2-3 
specific sialidase digestion on resting and 
recently activated CTL clone A10 in order to 
relatively quantify the ratio of α2,3-NeuAc/α2,6-
NeuAc residues between these different 
conditions. 
Fig. 7 depicts the MALDI-TOF mass 
spectra of permethylated N-glycans of CTL 
clone A10 in resting and recently activated states 
after sialidase-S (α2-3 specific) digestion. 
Comparing the ratio of sialylation to the base 
core fucosylated bi-antennary N-glycan (m/z 
2244) we found that resting state CTL clone A10 
was characterized by a high abundance of mono-
sialylated (m/z 2605, 2850, 3054 and 3299) and 
di-sialylated (m/z 2966) N-glycans (Fig. 7A). On 
the contrary, the recently activated CTL clone 
A10 exhibited a lower abundance of mono- and 
di-sialylated N-glycans (Fig. 7B). These data 
suggest that the recently activated CTL clone 
A10 has N-glycans with lower abundance of 
α2,6-linked NeuAc residues than the resting 
state. This ratio was found to be ~106% lower in 
the recently activated CTLs. 
The abundance of α2,6-linked NeuAc is 
directly correlated with the abundance of the 6-
linked galactose residue. Therefore, we 
performed GC-MS linkage analysis on both the 
resting and recently activated CTL clone A10 in 
order to detect any possible difference in the 
abundance of 6-linked galactose residues. The 
results suggested that recently activated CTL 
clones A10 contained 56% less 6-linked 
galactose residue compared with their resting 
state (data not shown). Taken altogether, the 
data suggested that recently activated CTLs 
contained less α2,6-linked NeuAc residues than 
their resting state CTLs. 
DISCUSSION 
Defining the underlying 
immunosuppressive mechanisms of how tumor 
microenvironment impairs TIL function is of 
great importance. The level of galectins, 
abundant in solid tumors, has been correlated 
with the aggressiveness of the tumor and it has 
been hypothesized that they might modulate 
tumor progression and influence the disease 
outcome (19, 20). This suggestion appears to 
hold true because cells highly regulate the 
expression of endogenous galectins and their 
ligands in order to regulate cellular functions, 
suggesting that exogenous galectins or 
modification in the expression of galectin 
ligands could lead to pathology (21). The results 
presented here, have been obtained with clones 
and therefore are expected to be more rigorous 
than polyclonal splenocytes that may contain 
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different cell types. Applying ultra-sensitive 
MALDI-TOF-MS, combined with various 
glycosidase digestions and GC-MS linkage 
analyses, we make the novel observation that the 
N-glycome of the recently activated human 
CD8+ CTLs, when compared with the N-
glycome of the resting CTLs: (i) consists of 
longer LacNAc chains of which a portion are 
longer that four units ((LacNAc)4, poly-
LacNAcs); (ii) contains more branched (multi-
antennary) N-glycans. These observations verify 
our working hypothesis that activation of human 
CTLs and TILs results in the expression of 
surface glycoproteins that exhibit higher 
abundance of galectin-3 ligands and possibly 
other galectin ligands such as galectin-1. This 
combined with the high abundance of 
extracellular galectin-3 found in tumor 
microenvironments could potentially explain the 
loss of TIL functions through a mechanism of 
reduced motility of surface molecules. 
Galectin-3 is a β-galactoside binding lectin 
that binds to internal LacNAc repeats and it is 
not severely affected by the terminal epitopes at 
the non-reducing end of long-LacNAc extended 
glycans (22, 23). Therefore binding to the long 
poly-LacNAc chains is not affected by the 
variations of the abundance of sialic acids, sLex 
and Lex epitopes found here. Thus, our data 
suggest that on the recently activated CTLs the 
increased abundance of LacNAc repeats 
increases the galectin-3-LacNAc interactions 
and blocks the mobilization of various 
glycoproteins. Simultaneously, galectin-3 is a 
lectin that possesses multivalent carbohydrate 
binding and cross-linking activity (24). 
Surprisingly, on the recently activated CTLs, 
these poly-LacNAc extensions were found to be 
more abundant on tri-antennary N-glycans with 
GlcNAcβ1-2(GlcNAcβ1-4)Manβ1-
3(GlcNAcβ1-2Manβ1-6)Man branches and less 
abundant on tetra-antennary N-glycans, while 
resting CTLs exhibited reduced abundance of 
these tri- and tetra-antennary branches. Most 
interestingly, our data suggest that these poly-
LacNAc repeats appeared to be mainly equally 
distributed on all available N-glycan branches 
and not selectively enriched on a specific N-
glycan branch. The above suggest that recently 
activated human CTLs can form more 
multivalent galectin-3-LacNAc lattices, a fact 
that combined with the high levels of galectin-3 
found in tumor microenvironments, could 
further explain the reduced motility of surface 
glycoproteins. 
Our results are consistent with previous 
mouse studies highlighting the importance of N-
glycosylation and specifically how LacNAc 
abundance and branching could block T cell 
activation by regulating the mobility of key 
surfaces molecules, such the TCR (9). However, 
those data suggested the selective extension of 
LacNAc repeats on the β1,6-GlcNAc branch, 
something that has not been verified from our 
data. Considering the data obtained here, it is 
possible that variations of LacNAc extensions 
are taking place on all available branches of 
mouse N-glycans, but only variations of the 
β1,6-branch were detected by the Phaseolus 
vulgaris leukoagglutinin binding lectin (9, 25). 
The possibility that mouse TCR is specifically 
decorated either with tri-antennary N-glycans of 
type GlcNAcβ1-2(GlcNAcβ1-6)Manβ1-6Man or 
tetra-antennary N-glycans, cannot be excluded. 
In such a case, a possible down-regulation of the 
Mgat5 gene would provoke a reduced abundance 
of the LacNAc “density” which is expected to 
decrease the galectin-3-LacNAc lattices. 
A major surface glycoprotein that could be 
affected from the above galectin-3-LacNAc 
lattices is the TCR. In the recently activated 
human CTLs, characterized by the loss of 
effector functions and the absence of co-
localization of TCR and CD8, the TCR was 
found in close proximity to galectin-3. A 
treatment of these CTL with galectin ligands 
(LacNAc) resulted within 2 h in TCR/CD8 co-
localization, detaching the galectin-3 from the 
TCR and was accompanied by restored functions 
(8). This suggests that galectin-3, which is 
involved in distancing the TCR from CD8 (8), 
could potentially regulate CTLs functions. 
Several lines of evidence support this concept 
meaning that loss of effector functions on human 
CTLs could be associated with the galectin-3-
LacNAc-TCR lattices. First, treatment of human 
TIL with anti-galectin-3 antibody detached 
galectin-3 from cells and boosted their functions 
(6). Second, human TCR α-chain, in contrast to 
β-chain, has been shown to be occupied 
exclusively by complex N-glycans (26). Third, a 
previous study showed that the removal of a N-
glycosylation site from the human TCR α-chain, 
resulted in improved sensitivity of a T cell 
response (functional avidity) (11). Finally and 
most importantly, a key step in T cell effector 
function is the phosphorylation of 
Glycomics on Human Cytolytic T Lymphocytes 
10 
 
immunoreceptor tyrosine-based activation 
motifs (ITAMs) within the CD3 complex, which 
in turn is depended on LCK activation (27). 
However, a recent study has shown that LCK is 
already activated in resting human T cells, 
enough to initiate TCR signaling (28). 
Moreover, the expression-activation of LCK did 
not appear to depend on TCR or co-receptor 
expression-contact with pMHC. Hence, the 
above collectively suggest that the increased 
galectin-3-LacNAc lattices occurring in the 
recently activated CTLs and accompanied by the 
loss of effector functions could be linked, though 
not exclusively, to the de-localization of the 
TCR from the CD8 molecule. This in turn could 
potentially prevent the ITAMs phosphorylation 
by keeping the TCR-CD3 complex distant from 
LCK, which is stably associated with the CD8 
co-receptor (29) and therefore prevent further 
signaling. This concept has been already been 
shown in mouse studies. Mgat5-deficient mice 
after stimulation exhibited increased association 
of the Zap-70 kinase with ITAMs, compared 
with WT mice, exhibiting a negative regulation 
of galectin-3-LacNAc lattices and ITAM 
phosphorylation (9). 
Our data showed that the changes in 
LacNAc abundance between the resting and 
recently activated states of clone F3.2 were less 
prominent than those of clone A10. For TILs 
present in a tumor microenvironment of a given 
concentration of galectins and activated by the 
same peptide-MHC complex, the ones with a 
smaller increase in LacNAc abundance (such as 
clone F3.2) would be expected to present a 
relatively higher motility of surface molecules 
such as the TCR, compared to other TILs with a 
more pronounced increase in LacNAc 
abundance (such as of clone A10). This is 
because the reduced increase of LacNAc 
abundance should induce a reduced increase of 
galectin-3-LacNAc lattices and therefore should 
have a smaller impact on the motility of surface 
molecules. Hence, a reduced increase of 
LacNAc abundance in activated T cells would be 
expected to result in higher motility of surface 
molecules and possibly effector functions. This 
concept has already been proposed in a previous 
study suggesting that either the peptide-MHC 
complexes that would be predicted to overcome 
the negative regulation by the galectin lattice, or 
the reduced N-glycan branching that would 
reduce the interaction of TCR for galectin would 
lead to activation (30). 
Our data showed that recently activated 
human CD8+ CTL clones exhibited a lower 
abundance of terminal α2,6-linked NeuAc 
residues than resting CTLs. This fact is expected 
to affect galectin-1-glycoprotein binding 
interactions. Galectin-1 binds to terminal 
LacNAc units either in their unmodified state or 
when they are decorated with α2,3-linked 
NeuAc (31, 32), but this binding is blocked by 
α2,6-linked NeuAc (23, 33, 34). Therefore, our 
data suggest that more galectin-1-ligand binding 
interactions are expected to be formed in 
recently activated CTLs than in the resting 
CTLs. Interactions of the TCR with galectin-1, 
instead of galectin-3, that may contribute to 
lattice formation and restrain TCR function, 
cannot be excluded either. Indeed, we detected 
extracellular galectin-1, in addition to galectin-3 
and both have been detected in TILs (6). 
However, in a previous study, the anti-galectin-3 
monoclonal antibody B2C10, while being able 
to boost TIL function, seemed unable to detach 
galectin-1, suggesting that detaching galectin-3 
from TIL was sufficient to restore function, 
while not excluding the contribution of other 
galectins (6). Exactly how and if this could be 
related to loss of effector functions, related to 
TCR, on the recently activated human CTLs is 
currently unknown. Moreover, the possibility of 
additional molecules that contribute to the 
mechanism, such as the CD45, with galectin-1 
and/or galectin-3, cannot be excluded either (35, 
36). In mouse, the decreased abundance of α2,6-
linked sialic acids has been described in CD4+ 
and CD8+ T lymphocytes during activation and 
it has been suggested that this leads to increased 
binding with CD22 (siglec-2) and/or galectin-1 
(13). 
MALDI-TOF-MS suggested that O-glycans 
of recently activated human CTLs exhibited 
increased abundance of disialylated core 1 and 
monosialylated core 2 structures than the resting 
CTLs. The increased abundance of core 2 O-
glycans on recently activated CTLs is in 
accordance with previous studies showing 
increased abundance of core 2 O-glycans in 
human leukosialin after activation of human T 
cells (37). Exactly how and if changes in O-
glycosylation could be related to loss of effector 
functions in the recently activated human CTLs 
is currently unknown. Noteworthy, when our 
CTLs were activated and cultured for 4 days in 
the presence of swainsonine, an inhibitor of 
mannosidase II, neither their functions nor the 
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TCR-CD8 co-localization were lost (8). Previous 
studies have shown that changes in O-glycan 
structures could affect CD8 co-receptor 
signaling by either altering the conformation of 
its stalk region (38-40) or by regulating its 
avidity (41). Further studies will show if O-
glycosylation affects the loss of effector 
functions. 
In conclusion, our results show that the N-
glycome of the recently activated CTL clones, 
after antigenic stimulation, result in increased 
abundance-“density”- of poly-LacNAc chains 
that is able to sustain galectin-3 lattices, without 
excluding the participation of other galectins, 
and reduce the motility of key surface 
molecules, such as the TCR that is accompanied 
by the loss of effector functions of TIL. The 
possibility that certain surface glycoproteins do 
not follow the alteration of glycosylation 
presented here cannot, however, be excluded 
either. 
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FIGURE LEGENDS 
 
FIGURE 1. LacNAc treatment of human CTL can restore their ability to secrete IFN-γ .  Resting 
CTL clones were expanded by stimulation every two weeks with peptide-pulsed EBV-B cells, in the 
presence of feeder cells and IL-2. To assess effector functions, 10,000 CTL were collected, either at 
the resting state (± two weeks after stimulation) or in an activated state (four days after stimulation). 
CTL were incubated (or not) for 2 h with LacNAc (2 mM) and subsequently stimulated with peptide-
pulsed HLA-A1 cells. IFN-γ was measured by ELISA in the supernatant of overnight cocultures. 
 
FIGURE 2. MALDI-TOF mass spectra of permethylated N-glycans of CTL clone A10 derived 
from resting and recently activated state. N-glycomic profiles of A, resting; and B, recently 
activated CTL clone A10 were obtained from the 50% MeCN fraction from a C18 Sep-Pak column 
(“Experimental Procedures”). Annotated structures are according to the Consortium for Functional 
Glycomics (http://www.functionalglycomics.org) guidelines. All molecular ions are [M+Na]+. 
Putative structures based on composition, tandem MS and the biosynthetic knowledge. Structures that 
show sugars outside a bracket have not been unequivocally defined. 
 
FIGURE 3. MALDI-TOF mass spectra of permethylated O-glycans of CTL clone A10 derived 
from resting and recently activated state. O-glycomic profiles of A, resting; and B, recently 
activated CTL clone A10 were obtained from the 35% MeCN fraction from a C18 Sep-Pak column 
(“Experimental Procedures”). Annotated structures are according to the Consortium for Functional 
Glycomics (http://www.functionalglycomics.org) guidelines. All molecular ions are [M+Na]+. 
Putative structures based on composition, tandem MS and the biosynthetic knowledge. 
 
FIGURE 4. Low mass MALDI-TOF spectra of permethylated N-glycans derived from endo-β-
galactosidase digestion of resting and recently activated CTL clone A10. N-glycomic profiles of 
CTL clone A10 in A, resting; and B, recently activated states. Profiles of N-glycans are from the 35% 
MeCN fraction from a C18 Sep-Pak (“Experimental Procedures”). All molecular ions are [M+Na]+. 
Putative structures based on composition, tandem mass spectrometry and the literature shown. 
Annotated structures are according to the Consortium for Functional Glycomics 
(http://www.functionalglycomics.org) guidelines. Not annotated peaks correspond to non-glycan 
structures or to matrix peaks. 
 
FIGURE 5. Middle mass MALDI-TOF spectra of permethylated N-glycans derived from endo-
β-galactosidase digestion of resting and recently activated CTL clone A10. N-glycomic profiles of 
CTL clone A10 in A, resting; and B, recently activated states. Profiles of N-glycans are from the 35% 
MeCN fraction from a C18 Sep-Pak (“Experimental Procedures”). All molecular ions are [M+Na]+. 
Putative structures based on composition, tandem mass spectrometry and the literature shown. 
Annotated structures are according to the Consortium for Functional Glycomics 
(http://www.functionalglycomics.org) guidelines. 
 
FIGURE 6. Long polylactosamine units are more abundant on recently activated CTL clone F3.2 
N-glycans. A, Expected resulting N-glycans of resting and recently activated CTLs after HF and 
sialidase treatments (upper panel structure) and additionally after two consecutive cycles of 
galactosidase (G) and β-N-acetylhexosaminidase (H) treatments and one endo-β-galactosidase (endo) 
treatment (lower panel structure). B, N-glycomic profile of CTL clone F3.2 of resting (upper panel) 
and recently activated states (lower panel). Profiles of N-glycans are from the 50% MeCN fraction 
from a C18 Sep-Pak. All molecular ions are [M+Na]+. Putative structures based on composition, 
tandem mass spectrometry and the literature shown. Annotated structures are according to the 
Consortium for Functional Glycomics (http://www.functionalglycomics.org) guidelines. Note that the 
most abundant long polylactosamine units (higher than 4 LacNAc units long) are found at m/z 2081 
that corresponds to a tri-antinnary N-glycan structure. 
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FIGURE 7. Recently activated CTL clone A10 contains less α2,6-linked NeuAc residues than the 
resting CTL. Partial MALDI-TOF mass spectra of permethylated N-glycans derived from A, resting; 
and B, recently activated CTL clone A10 after treatment with sialidase-S (α2-3 specific). N-glycomic 
profiles were obtained from the 50% MeCN fraction from a C18 Sep-Pak column (“Experimental 
Procedures”). All molecular ions are [M+Na]+. Putative structures based on composition, tandem MS 
and the literature shown. Annotated structures are according to the Consortium for Functional 
Glycomics (http://www.functionalglycomics.org) guidelines. 
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TABLES 
 
TABLE 1. GC-MS linkage analyses of partially methylated alditol acetates obtained from the 
PNGase F released N-linked glycans of CTL clones A10 and F3.2. Desialylated (Sialidase-A, non-
specific) permethylated N-glycans were hydrolyzed, reduced, acetylated and analyzed by GC-MS (see 
“Experimental Procedures”). 
 
CTL 
clones 
Relative abundancea % Difference (on activated)b 
3-Gal 4-GlcNAc 3,4-GlcNAc 3-Gal 4-GlcNAc 3,4-GlcNAc 
 Resting R. Activated 
Resting 
R. Activated 
Resting 
R. Activated 
   
A10 0.279 0.616 
0.086 
0.382 
0.008 
0.037 +121% +344% +363% 
F3.2 0.273 0.403 
0.184 
0.311 
0.024 
0.031 +48% +69% +29% 
 
aUpper panel values express the resting state CTLs relative abundance; lower panel values express the 
recently activated CTLs relative abundance. Relative abundance of 3-linked Gal, 4-linked GlcNAc 
and 3,4-linked GlcNAc were obtained normalizing the integrated area peak of the extracted ion 
current (XIC) chromatogram of a specific residue to the summed integrated areas of the XICs of 3,6-
linked mannose and 3,4,6-linked mannose. 
 
bPercent difference of the relative abundance between resting and recently activated CTL clones, 
(recently activated - resting)/resting%. 
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